Relationship of phosphate administration to serum and red cell phosphate concentration, erythrocyte 2,3-diphosphoglycerate (2,3-DPG) and blood P50 in the hyperglycemic dog.
In vitro studies indicate that acute increases in intracellular phosphate concentration decrease red blood cell 2,3-diphosphoglycerate levels (G. Momsen, B. Vestergaard-Bogind, Arch Biochem Biophys 190:67, 1978). We have examined the relationship in vivo of serum phosphate concentration, red cell phosphate, 2,3-DPG and blood P50 in hyperglycemic dogs infused alternately with phosphate or chloride (control) solutions. During the 8-hr insulin infusion, serum phosphate (Pi) fell 40% in the chloride-treated animals and rose 71% in the phosphate-treated dogs (P less than 0.001, phosphate vs. control). RBC Pi concentration declined in the controls and rose significantly in the phosphate-infused dogs (P less than 0.02). Serum Pi and RBC Pi were correlated in the phosphate-managed animals (r = 0.76, P less than 0.02), but not in the controls. RBC 2,3-DPG failed to rise in either group during insulin infusion and regression analysis showed a negative correlation between serum Pi and 2,3-DPG (r = -0.90, P less than 0.005) and between RBC Pi concentration and 2,3-DPG (r = -0.84, P less than 0.02). P50 failed to change in either group during insulin treatment and for up to 24 hr after initiation of the 8-hr infusion of insulin.
D019794:2,3-Diphosphoglycerate; D000818:Animals; D001784:Blood Gas Analysis; D004163:Diphosphoglyceric Acids / Q000097:blood*; D004285:Dogs; D004912:Erythrocytes / Q000032:analysis*; D006943:Hyperglycemia / Q000097:blood* / Q000188:drug therapy; D007328:Insulin / Q000627:therapeutic use; D010710:Phosphates / Q000097:blood / Q000494:pharmacology*; D011188:Potassium / Q000097:blood
D004163:Diphosphoglyceric Acids; D007328:Insulin; D010710:Phosphates; D019794:2,3-Diphosphoglycerate; D011188:Potassium